Brief: HLS Therapeutics Announces Normal Course Issuer Bid
09/05/2018 22:13
May 9 (Reuters) - HLS Therapeutics Inc HLS.V :
* HLS THERAPEUTICS ANNOUNCES NORMAL COURSE ISSUER BID
* HLS THERAPEUTICS - PURSUANT TO NORMAL COURSE ISSUER BID,
CO MAY
PURCHASE FOR CANCELLATION UP TO AGGREGATE OF 1.4 MILLION OF ITS
ISSUED & OUTSTANDING SHARES
Source text for Eikon: ID:nCNWbd2l7a
Further company coverage: HLS.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group